Aeon Biopharma IncAEON
ASignal's systematic analysis rates AEON as Neutral.
Reflects the latest available analysis · analyzed Aug 21, 2026
The case on AEON
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Low RSI (7.63) indicating potential oversold condition
- Positive MACD histogram suggesting weakening bearish momentum
- Cash position exceeds debt ($3.43M vs $2.77M)
- Strong downtrend with price below SMA20, SMA50, and EMA20
- Negative price momentum (-0.303)
- Negative enterprise value to EBITDA (-0.45x)
- Negative return on assets (-141.53%)
- Operating and free cash flow deeply negative
- Current and quick ratios below 1.0 indicating liquidity risk
See the full verdict on AEON
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AEON
Most investors never get a second opinion, let alone several. ASignal runs AEON past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.